Lovenox still needs a defense strategy to hold share, but it requires less investment as a specialty product. Instead, Lovenox should throw cash over to Acomplia, the putative future star of the Sanofi-Aventis portfolio.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial